This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2020-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2025
Title: Wei Lu: Innovator in Demyelinating Disease Research
Introduction
Wei Lu is a prominent inventor based in Rockville, MD (US). He has made significant contributions to the field of medical research, particularly in the area of demyelinating diseases. With a total of 2 patents, his work focuses on innovative protein compositions and their applications in treatment.
Latest Patents
Wei Lu's latest patents include compositions and methods involving myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein. These patents disclose a protein comprising no more than three human autoantigenic proteins. The first protein is a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence. The second is a myelin basic protein (MBP) amino acid sequence, and the third is a truncated proteolipid protein (PLP) amino acid sequence. Additionally, the patents cover related nucleic acids, pharmaceutical compositions, methods of treating demyelinating diseases, and methods of producing these proteins.
Career Highlights
Wei Lu works for the United States of America, as represented by the Secretary, Department of Health and Human Services. His research has been pivotal in advancing the understanding and treatment of demyelinating conditions.
Collaborations
Some of his notable coworkers include Lixin Zheng and Jae W Lee. Their collaborative efforts have contributed to the success of their research initiatives.
Conclusion
Wei Lu's innovative work in the field of demyelinating diseases showcases his dedication to advancing medical science. His patents reflect a commitment to developing effective treatments that can significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
